Previous close | 64.60 |
Open | 64.65 |
Bid | 46.50 x 200 |
Ask | 82.75 x 200 |
Day's range | 64.58 - 64.65 |
52-week range | 7.25 - 64.72 |
Volume | |
Avg. volume | 2,264,783 |
Market cap | 4.235B |
Beta (5Y monthly) | 1.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Earnings at CarMax miss analysts’ estimates, Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Robinhood stock is downgraded, and Nike receives an upgrade.